优化容积旋转调强与质子调强在局部晚期非小细胞肺癌胸部放疗中保护心脏亚结构的研究
结果显示心脏优化VMAT较原VMAT显著改善所有心脏结构的剂量,同时维持或改善肺、食管、脊髓约束及PTV覆盖;IMPT在部分心脏剂量指标上进一步优于心脏优化VMAT。
要点
- 心脏优化VMAT可显著降低所有心脏亚结构剂量并维持靶区覆盖。
- 心脏优化VMAT同时维持或改善肺、食管和脊髓的剂量约束。
- IMPT在部分心脏剂量指标上较心脏优化VMAT有额外改善。
核心结论
- 将心脏亚结构纳入优化的高质量VMAT计划可全面改善危及器官剂量,尤其是对关键心脏结构的大幅保护。
- IMPT较心脏优化VMAT提供部分剂量学增量改善,但其临床意义尚不确定。
研究设计与样本
- 为所有患者回顾性勾画心脏亚结构(包括瓣膜、房室结、冠状动脉、心腔和大血管),并制定心脏优化VMAT计划。
- 采用配对t检验比较心脏优化VMAT与原VMAT的剂量学变量,并同样比较心脏优化VMAT与IMPT计划。
主要发现
- 与原始VMAT计划相比,心脏优化VMAT计划在所有心脏结构上均显示出统计学显著改善。
- 心脏优化VMAT在维持或改善肺、食管和脊髓的适当约束以及PTV覆盖目标的同时,实现了心脏结构的剂量改善。
- 与心脏优化VMAT相比,IMPT在部分心脏剂量学指标上显示出额外的统计学显著改善,同时维持或改善其他胸部危及器官约束。
临床怎么用
- VMAT广泛可用,在优化过程中纳入心脏亚结构可提供危及器官剂量的全面改善,特别是对关键心脏结构的大幅保护。
- IMPT可作为心脏优化VMAT之外的增量剂量学选择,但其临床意义尚需进一步明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increasing radiation dose to the heart is associated with worse survival in stage III non-small cell lung cancer. We sought to evaluate the ability of optimized volumetric modulated arc therapy (VMAT) and intensity modulated proton therapy (IMPT) to spare cardiac substructures. We also wanted to determine how a cardiac optimization treatment planning algorithm influences dose distribution to other thoracic organs at risk (OARs). METHODS AND MATERIALS: Cardiac substructures were retrospectively contoured for all patients with stage III non-small cell lung cancer who were treated at our institution with VMAT to 60 Gy in 2-Gy fractions. The structures included valves, atrioventricular node, coronary arteries, chambers, and great vessels. New cardiac-optimized VMAT plans were created to spare these structures while preserving planning target volume coverage and maintaining standard dose constraints to OARs. Dosimetry variables for the new cardiac-optimized VMAT plans were compared via paired t test with the original VMAT plans. IMPT plans were also created, and the cardiac-optimized VMAT plans were then similarly compared with the IMPT plans. RESULTS: Twenty-six patients who were treated from July 2013 to September 2017 were included. Compared with the original VMAT plans, statistically significant improvements were demonstrated for all cardiac structures for the new cardiac-optimized VMAT plans while maintaining or improving appropriate lung, esophagus, and spinal cord constraints and planning target volume coverage goals. Compared with cardiac-optimized VMAT, IMPT demonstrated additional statistically significant improvements for some cardiac dosimetry metrics while maintaining or improving other thoracic OAR constraints. CONCLUSIONS: VMAT is now widely available, and high-quality VMAT plans that incorporate cardiac substructures into the optimization process can provide overall improvements in dose to OARs and, in particular, substantial sparing of critical cardiac structures. IMPT provides some incremental dosimetric improvements beyond cardiac-optimized VMAT, the clinical significance of which remains uncertain.
引用
- Ferris MJ, Martin KS, Switchenko JM, et al. Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer. Pract Radiat Oncol. 2019. PMID: 31077884. doi:10.1016/j.prro.2019.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。